IL242386B - Use of Aribolin and Lavetinib as a combination therapy for cancer treatment - Google Patents
Use of Aribolin and Lavetinib as a combination therapy for cancer treatmentInfo
- Publication number
- IL242386B IL242386B IL242386A IL24238615A IL242386B IL 242386 B IL242386 B IL 242386B IL 242386 A IL242386 A IL 242386A IL 24238615 A IL24238615 A IL 24238615A IL 242386 B IL242386 B IL 242386B
- Authority
- IL
- Israel
- Prior art keywords
- lenvatinib
- eribulin
- cancer
- treatment
- combination therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title 1
- 229960003649 eribulin Drugs 0.000 title 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 title 1
- 229960003784 lenvatinib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839542P | 2013-06-26 | 2013-06-26 | |
| PCT/JP2014/067723 WO2014208774A1 (en) | 2013-06-26 | 2014-06-26 | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL242386B true IL242386B (en) | 2019-06-30 |
Family
ID=51210708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL242386A IL242386B (en) | 2013-06-26 | 2015-11-01 | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9549922B2 (enExample) |
| EP (1) | EP3013335B1 (enExample) |
| JP (1) | JP6404242B2 (enExample) |
| KR (1) | KR102265952B1 (enExample) |
| CN (1) | CN105338977B (enExample) |
| AU (1) | AU2014299699B2 (enExample) |
| BR (1) | BR112015029386B1 (enExample) |
| CA (1) | CA2915005C (enExample) |
| ES (1) | ES2705698T3 (enExample) |
| IL (1) | IL242386B (enExample) |
| RU (1) | RU2672585C2 (enExample) |
| WO (1) | WO2014208774A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2415470T1 (sl) | 2009-03-30 | 2016-12-30 | Eisai R&D Management Co., Ltd. | Liposomski sestavek |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| JP6951248B2 (ja) * | 2015-03-04 | 2021-10-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| CN105832732A (zh) * | 2016-05-30 | 2016-08-10 | 青岛云天生物技术有限公司 | 一种用于胃癌治疗的药物组合物及其应用 |
| CN110139866B (zh) * | 2017-01-02 | 2022-05-17 | 研成精密化学株式会社 | 用于制备甲磺酸艾日布林的中间体以及制备其的方法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN107973804B (zh) * | 2017-11-29 | 2020-07-03 | 戊言医药科技（上海）有限公司 | 艾瑞布林中间体的合成方法 |
| SG11202006617RA (en) * | 2018-01-10 | 2020-08-28 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of hepatocellular carcinoma |
| CN109793736A (zh) * | 2019-01-31 | 2019-05-24 | 徐州医科大学 | 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用 |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN114028394A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | 低剂量仑伐替尼在制备治疗肝癌的药物中的用途 |
| US20250064794A1 (en) * | 2021-08-10 | 2025-02-27 | Eisai R&D Management Co., Ltd. | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| IL139960A0 (en) | 1998-06-17 | 2002-02-10 | Eisai Co Ltd | Macrocylic analogs and methods of their use and preparation |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| JP4542783B2 (ja) | 2002-03-05 | 2010-09-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤 |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| CN100569753C (zh) | 2003-12-25 | 2009-12-16 | 卫材R&D管理有限公司 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的甲磺酸盐的结晶（c）及其制备方法 |
| CN101899026B (zh) * | 2004-06-03 | 2016-08-03 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| JPWO2007052849A1 (ja) | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用 |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| ES2670423T3 (es) * | 2007-07-25 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Inhibidores de multicinasas para uso en el tratamiento de cáncer |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| MX2010008187A (es) | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
| BR112012018232B8 (pt) | 2010-01-26 | 2023-01-10 | Eisai R&D Man Co Ltd | Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US20120077837A1 (en) | 2010-09-24 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Anti-tumor agent |
| EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| ES2731653T3 (es) | 2011-03-18 | 2019-11-18 | Eisai R&D Man Co Ltd | Métodos y usos para predecir la respuesta a la eribulina |
| WO2012144463A1 (ja) * | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| WO2012154935A1 (en) | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
| EP3444363B1 (en) * | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| SG11201607298QA (en) | 2014-03-03 | 2016-09-29 | Eisai R&D Man Co Ltd | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| KR20170039096A (ko) | 2014-05-28 | 2017-04-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료에 있어서 에리불린의 용도 |
| JP6644479B2 (ja) | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 |
-
2014
- 2014-06-26 ES ES14739971T patent/ES2705698T3/es active Active
- 2014-06-26 CA CA2915005A patent/CA2915005C/en active Active
- 2014-06-26 EP EP14739971.1A patent/EP3013335B1/en active Active
- 2014-06-26 KR KR1020167001713A patent/KR102265952B1/ko active Active
- 2014-06-26 CN CN201480036218.0A patent/CN105338977B/zh active Active
- 2014-06-26 JP JP2015562231A patent/JP6404242B2/ja active Active
- 2014-06-26 WO PCT/JP2014/067723 patent/WO2014208774A1/en not_active Ceased
- 2014-06-26 RU RU2016102158A patent/RU2672585C2/ru active
- 2014-06-26 AU AU2014299699A patent/AU2014299699B2/en active Active
- 2014-06-26 BR BR112015029386-7A patent/BR112015029386B1/pt active IP Right Grant
- 2014-06-26 US US14/315,930 patent/US9549922B2/en active Active
-
2015
- 2015-11-01 IL IL242386A patent/IL242386B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2705698T3 (es) | 2019-03-26 |
| JP6404242B2 (ja) | 2018-10-10 |
| WO2014208774A1 (en) | 2014-12-31 |
| CN105338977B (zh) | 2018-10-16 |
| US20150005343A1 (en) | 2015-01-01 |
| KR20160023816A (ko) | 2016-03-03 |
| RU2672585C2 (ru) | 2018-11-16 |
| CN105338977A (zh) | 2016-02-17 |
| CA2915005C (en) | 2021-12-28 |
| RU2016102158A (ru) | 2017-07-31 |
| BR112015029386B1 (pt) | 2023-11-14 |
| JP2016528162A (ja) | 2016-09-15 |
| CA2915005A1 (en) | 2014-12-31 |
| US9549922B2 (en) | 2017-01-24 |
| AU2014299699A1 (en) | 2015-12-10 |
| BR112015029386A2 (pt) | 2017-07-25 |
| KR102265952B1 (ko) | 2021-06-16 |
| AU2014299699B2 (en) | 2019-10-10 |
| BR112015029386A8 (pt) | 2020-03-17 |
| EP3013335B1 (en) | 2018-11-07 |
| EP3013335A1 (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| IL239007A0 (en) | Use of Aribolin to treat breast cancer | |
| IL239453B (en) | Preparations and methods for treating cancer using bacteria | |
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| SMT201900024T1 (it) | Terapia combinata per il trattamento di cancro | |
| PT3060211T (pt) | Tratamento de cancro e distúrbios proliferativos benignos. | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| GB201607581D0 (en) | Treatment of cancer | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| PL3010513T3 (pl) | Skojarzenie RO5503781 i kapecytabiny do leczenia raka | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane | |
| GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| IL233495A0 (en) | Combination for cancer treatment | |
| GB201305020D0 (en) | Treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |